What is Muse?
Muse operates at the forefront of the neurotechnology industry, specializing in the development of sophisticated EEG devices designed to monitor brain activity in real-time. By translating neurological signals into auditory feedback, the company provides users with a tangible method to cultivate mindfulness and meditation practices. Beyond consumer applications, Muse has pivoted toward the enterprise sector, offering scientifically validated programs that assist organizations in fostering healthier work environments. Their hardware-software ecosystem is engineered to lower employee stress, enhance cognitive focus, and improve overall engagement, positioning the company as a critical player in the burgeoning corporate mental health technology landscape.
How much funding has Muse raised?
Muse has raised a total of $38.3M across 4 funding rounds:
Angel/Seed
$1.2M
Series A
$6M
Series B
$21.6M
Series C
$9.5M
Angel/Seed (2012): $1.2M, investors not publicly disclosed
Series A (2013): $6M, investors not publicly disclosed
Series B (2017): $21.6M supported by OMERS Ventures and Export Development Canada
Series C (2022): $9.5M featuring Alabaster and Export Development Canada
Key Investors in Muse
Export Development Canada
Export Development Canada is a financial institution founded in 1944 that provides risk management, secure financing, and working capital services to support international business growth.
OMERS Ventures
OMERS Ventures is a prominent investment group that manages pension-backed capital, focusing on high-growth technology companies with significant market potential.
Alabaster
Alabaster Publishing is a mission-driven organization that provides strategic support and resources, often operating with a focus on long-term value creation and community impact.
What's next for Muse?
With the successful closure of this major strategic investment, Muse is well-positioned to accelerate its product development roadmap and expand its footprint within the global enterprise wellness market. The company is expected to focus on deepening its integration with corporate health platforms, potentially leveraging its proprietary data to offer more personalized resilience training. As the demand for evidence-based mental health interventions continues to rise, Muse's ability to provide measurable outcomes through its EEG technology will likely serve as a key competitive advantage. Future growth will likely involve scaling its sales infrastructure and enhancing its software-as-a-service offerings to meet the complex needs of large-scale organizations seeking to improve workforce productivity and mental well-being.
See full Muse company page
